Why PreludeDx’s second FDA breakthrough device designation matters for precision diagnostics
Breast cancer care needs sharper radiation decisions. PreludeDx’s AidaBREAST now faces the harder test of validation, adoption and access.
What Juniper Biosciences’ MSK collaboration means for radiation dose de-escalation strategies
Find out how Juniper Biosciences is using FMISO imaging to personalize radiation therapy and reduce toxicity in head and neck cancer.
Can PreludeDx and Quanterix turn AidaBREAST into a new standard for radiation therapy decisions
See why AidaBREAST could reshape breast cancer radiation decisions and put spatial proteomics closer to routine oncology use.
GT Medical Technologies’ BRIDGES trial begins enrollment, testing GammaTile in newly diagnosed glioblastoma patients
GT Medical Technologies has announced the first patient enrollments in its BRIDGES trial, a randomized clinical study assessing the use of GammaTile therapy in newly diagnosed glioblastoma. The trial introduces GammaTile at the time of initial tumor resection, marking a notable shift from the conventional glioblastoma radiation timeline, which typically delays radiation until several weeks […]
Kallisio’s Stentra system enters clinical use at Stanford, expanding precision radiation toolkit for head and neck cancer
Kallisio has begun clinical implementation of its FDA-cleared Stentra system at Stanford Health Care, marking the first reported integration of the patient-specific intraoral device into a major U.S. hospital’s workflow for head and neck cancer radiation therapy. The system, which received 510(k) clearance in January 2024, enables individualized immobilization of oral structures during intensity-modulated radiation […]
How AidaBreast’s multi-omic insights may reduce overtreatment in breast cancer care
Prelude Corporation has announced the first independent validation of AidaBreast, a multi-omic diagnostic test developed to predict both locoregional recurrence risk and individualized radiation therapy benefit in early-stage hormone receptor-positive, HER2-negative invasive breast cancer. The study, conducted at Royal Melbourne Hospital and presented at the San Antonio Breast Cancer Symposium 2025, evaluated over 400 women […]